FAQ / EVIDENCE & SAFETY STATES
CJC-1295: the questions, answered from the record
Safety, side effects, legal status, and the testosterone questions — each answered directly from the published literature, with the gaps marked rather than papered over.
Safety and side effects
These answers foreground what the record does and does not establish. Where a claim is a gap rather than a finding, it is labeled as one.
Is CJC-1295 safe?
There is no adequate long-term human safety data, and CJC-1295 is unapproved for human use by any major regulator. Theoretical and documented concerns include fluid retention and edema (GH-driven sodium retention), modestly increased cancer-risk signals tied to sustained IGF-1 elevation, and immunogenicity flagged by the FDA at the 2024 Pharmacy Compounding Advisory Committee.
Are CJC-1295 peptides safe?
No long-term human safety data establish this. The published human record is limited to short early PK studies [1][3]; sustained GH/IGF-1 elevation carries theoretical risks (fluid retention, IGF-1/cancer-risk epidemiology), and the FDA has cited immunogenicity concerns at the 2024 Pharmacy Compounding Advisory Committee.
What are the side effects of CJC-1295?
Reported and theoretical concerns center on GH-axis stimulation: fluid retention and edema (GH increases renal sodium reabsorption), effects on insulin sensitivity, and — from sustained IGF-1 elevation — the cancer-risk signal seen in IGF-1 epidemiology. The FDA has also flagged immunogenicity.
Documented and theoretical concerns
The candid safety picture for CJC-1295 has four parts. First, GH-axis stimulation can cause fluid retention, edema, and shifts in insulin sensitivity. Second, sustained IGF-1 elevation maps onto epidemiology linking higher IGF-1 to modestly increased risk of certain cancers. Third, FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited immunogenicity and other concerns for GH secretagogues including CJC-1295. Fourth, there are no controlled long-term human safety studies, so the most honest statement is that the long-term risk profile in healthy adults is simply unknown [1].
Definitional and class questions
What is CJC-1295?
A synthetic analog of growth-hormone-releasing hormone built on hGRF(1-29) with four protease-resistant substitutions [7]. The DAC variant is covalently bound to serum albumin for a multi-day half-life [2]; the no-DAC form ("Modified GRF 1-29") is short-acting [8].
What does CJC-1295 do?
It binds the GHRH receptor on pituitary somatotrophs and stimulates pulsatile growth-hormone release, which raises hepatic IGF-1. In healthy men a single dose raised mean GH approximately 46% and IGF-1 approximately 45% a week later [3].
Is CJC-1295 a steroid?
No. It is a peptide — a synthetic GHRH analog that acts upstream on the pituitary to release the body's own growth hormone. It is not an anabolic-androgenic steroid and does not act on androgen receptors.
Regulatory and legal status
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved for human use by the FDA or any major regulator and is handled as a research chemical. At the 2024 FDA Pharmacy Compounding Advisory Committee it was reviewed and not recommended for the 503A compounding bulks list, with immunogenicity cited among the concerns.
CJC-1295 is also prohibited at all times in sport under Section S2 of the WADA Prohibited List (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and is banned by bodies such as the NCAA; detection assays are well established. CJC-1295 has in fact been identified by high-resolution LC-MS/MS as the active ingredient in a seized "GHRH" preparation in an anti-doping context [6], and reviews document the analytical methods used to detect GHRH synthetic analogs in sport [14][15].
CJC-1295 and the hormonal axes
The testosterone questions come up constantly, so here they are, plainly: CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis, and the published studies did not measure testosterone as an endpoint [1][3].
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the androgen axis; the published studies measure GH and IGF-1, not testosterone. There is no controlled human evidence that it raises or lowers testosterone.
Does CJC-1295 lower testosterone?
No controlled human study shows CJC-1295 lowering testosterone; it acts on the GH/IGF-1 axis rather than the gonadal axis, and the published trials did not track testosterone as an endpoint.
Does CJC-1295 raise testosterone?
There is no controlled human evidence that CJC-1295 raises testosterone. It targets the GH/IGF-1 axis — the published studies report GH and IGF-1 responses, not changes in testosterone.
Are peptides safer than TRT?
Not an answerable equivalence: testosterone-replacement therapy is an approved, monitored treatment with extensive data, whereas CJC-1295 is an unapproved research chemical with only short early-phase human PK data [1]. The closest approved GHRH-analog comparator is tesamorelin, studied in HIV-associated fat accumulation [13].